# US 2001/0025058 A1 · Water-soluble compositions of bioactive lipophilic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025058 A1
- Document ID: US20010025058A1
- Status: Published application
- Kind: A1
- Application number: 09/773,592
- Filed: 2001-02-02
- Published: 2001-09-27
- Earliest claimed: 2000-02-23
- Assignees: National Research Council of Canada
- Inventors: Henryk Borowy-Borowski; Marianna Sikorska-Walker; P. Roy Walker
- Web page: https://patentgrep.com/patent/US20010025058A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 31/01: Hydrocarbons
- A61K 31/015: carbocyclic
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61P 31/10: Antimycotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Water-soluble compositions comprising a lipophilic compound and a solubilizing agent of the general formula: {X—OOC—[(CH2)n—COO]m}p—Y (I) wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0 are disclosed. The lipophilic compound is preferably selected from the group consisting of water-insoluble ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, and mixtures thereof. The hydrophobic moiety is preferably a sterol or a tocopherol and the hydrophilic moiety is preferably a polyalkylene glycol. In some embodiments, the sterol is cholesterol or sitosterol, the tocopherol is α-(+)-tocopherol, the polyalkylene glycol is a polyethylene glycol or its methyl monoether having an average molecular weight between 400 and 1000, p is equal to 1 or 2, m is equal to 0 or 1 and n is an integer between 2 and 18.

## Claims

### Claim 1

A method for the treatment of a fungal infection in humans or warm-blooded animals in need of such treatment, comprising administering to such human or warm-blooded animal, a therapeutically effective amount of a water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-u.-tocopheryl sebacate, and a macrolide polyene antibiotic, formulated in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1, in conjunction with a pharmaceutically effective carrier or excipient.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the anitibiotic is selected from the group consisting of amphotericin B and nystatin.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the antibiotic is amphotericin B, and wherein the weight ratio of solubilizing agent to antibiotic is 3:1 to 4:1 w/w.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the antibiotic is nystatin, and wherein the weight ratio of solubilizing agent to antibiotic is 2:1 to 4:1 w/w.

### Claim 5

A water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-α-tocopheryl sebacate, and a macrolide polyene antibiotic, formulated in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1.

### Claim 6 (depends on 5)

A composition according to claim 5, wherein the antibiotic is selected from the group consisting of amphotericin B and nystatin.

### Claim 7 (depends on 5)

A composition according to claim 5, wherein the antibiotic is amphotericin B, and wherein the weight ratio of solubilizing agent to antibiotic is 3:1 to 4:1 w/w.

### Claim 8 (depends on 5)

A composition according to claim 5, wherein the antibiotic is nystatin, and wherein the weight ratio of solubilizing agent to antibiotic is 2:1 to 4:1 w/w.

### Claim 9 (depends on 7)

A composition according to claim 7, wherein the solubilizing agent is polyoxyethanyl-sitosterol sebacate.

### Claim 10 (depends on 7)

A composition according to claim 7, wherein the solubilizing agent is polyoxyethanyl-cholesteryl sebacate.

### Claim 11 (depends on 7)

A composition according to claim 7, wherein the solubilizing agent is polyoxyethanyl-α-tocopheryl sebacate.

### Claim 12 (depends on 8)

A composition according to claim 8, wherein the solubilizing agent is polyoxyethanyl-sitosterol sebacate.

### Claim 13 (depends on 8)

A composition according to claim 8, wherein the solubilizing agent is polyoxyethanyl-cholesteryl sebacate.

### Claim 14 (depends on 8)

A composition according to claim 8, wherein the solubilizing agent is polyoxyethanyl-α-tocopheryl sebacate.

### Claim 15 (depends on 5)

A method for preparing a water soluble composition according to claim 5, which method comprises the steps of,
(e) dissolving the antibiotic and the solubilizing agent in a water-miscible organic solvent, in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1,
(f) removing from the solution the organic solvent to achieve a desired concentration of the water soluble composition,
(g) dissolving the composition in water, and
(h) drying.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the antibiotic is amphotericin B, and wherein the weight ratio of solubilizing agent to antibiotic is 3:1 to 4:1 w/w.

### Claim 17 (depends on 15)

A method according to claim 15, wherein the antibiotic is nystatin, and wherein the weight ratio of solubilizing agent to antibiotic is 2:1 to 4:1 w/w.

### Claim 18 (depends on 15)

A method according to claim 15, wherein the solvent is methanol/acetic acid 3:1 v/v.

### Claim 19

A method for delivery of α-tocopherol to humans or warm-blooded animals in need thereof, comprising administering to such human or warm-blooded animal, an effective amount of a water-soluble form of vitamin E.

### Claim 20 (depends on 19)

A method according to claim 19, wherein the water-soluble form of vitamin E is polyoxyethanyl-α-tocopheryl sebacate.

### Claim 21

A water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-α-tocopheryl sebacate, and a compound having a high content of polyunsaturated fatty acids.

### Claim 22 (depends on 21)

A composition according to claim 21, wherein the compound is an oil, and wherein the solubilizing agent and oil are formulated in a weight ratio of solubilizing agent to oil of 2:1 to 3:1.

### Claim 23 (depends on 22)

A composition according to claim 22 wherein the oil is selected from the group consists of flaxseed oil and fish oil.

### Claim 24

A water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-α-tocopheryl sebacate, and a bioactive lipophilic compound selected from the group consisting of a terpene and a terpenoid.

### Claim 25 (depends on 24)

A composition according to claim 24, wherein the solubilizing agent and bioactive compound are formulated in a weight ratio of solubilizing agent to bioactive compound of 3:1 to 4:1.

### Claim 26 (depends on 25)

A composition according to claim 25, wherein the bioactive lipophilic compound is selected from the group consisting of squalene, geranoil, farnesol, β-carotene, astaxanthin, canthaxanthin, zeaxanthin, cryptoxanthin, lutein and lycopene.

### Claim 27 (depends on 25)

A composition according to claim 25, comprising polyoxyethanyl-α-tocopheryl sebacate and squalene, in a weight ratio of polyoxyethanyl-α-tocopheryl sebacate to squalene of 3:1.

### Claim 28 (depends on 25)

A composition according to claim 25, comprising polyoxyethanyl-α-tocopheryl sebacate and astaxanthin, in a weight ratio of polyoxyethanyl-α-tocopheryl sebacate to astaxanthin of 4:1.

### Claim 29 (depends on 28)

A method for preparing a water-soluble composition according to claim 28, comprising:
a) dissolving solubilizing agent and astaxanthin in a water-miscible organic solvent, in a weight ratio of solubilizing agent to astaxanthin of 4:1 to form a mixture;
b) diluting the mixture with water to form an aqueous solution;
c) concentrating the aqueous solution to remove the organic solvent and excess of water;

### Claim 30 (depends on 29)

A method according to claim 29, wherein step c) is effected by evaporation under reduced pressure.

### Claim 31

A water-soluble composition, comprising polyoxyethanyl-α-tocopheryl sebacate and α-tocopheryl acetate, formulated in a ratio of 2:1 to 5.5:1 w/w.

### Claim 32 (depends on 31)

A composition according to claim 31, comprising PCS-400 and α-tocopheryl acetate, formulated in a ratio of PCS-400 to α-tocopheryl acetate of 2:1 to 4.5:1 w/w.

### Claim 33 (depends on 31)

A composition according to claim 31, comprising PCS-600 and α-tocopheryl acetate, formulated in a ratio of PCS-600 to α-tocopheryl acetate of 5.5:1 w/w.

### Claim 34

A water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-α-tocopheryl sebacate and polyoxyethanyl tocotrienyl sebacate, and a tocotrienol, formulated in a ratio of solubilizing agent to tocotrienol of about 5.5:1 w/w.

### Claim 34 (depends on 34)

A composition according to claim 34, wherein the solubilizing agent is PTS-600.

### Claim 35 (depends on 34)

A composition according to claim 34, wherein the solubilizing agent is PtrienS-600.

### Claim 36

A water-soluble composition, comprising a solubilzing agent selected from the group consisting of polyoxyethanyl-α-tocopheryl sebacate and polyoxyethanyl tocotrienyl sebacate, and coenzyme Q10, formulated in a ratio of solubilizing agent to coenzyme Q10 of 2.5:1 to 3.5:1 w/w.

### Claim 37 (depends on 36)

A composition according to claim 36, wherein the solubilizing agent is PTS-400, and wherein the ratio of PCS-400 to coenzyme Q10 is 2.5:1 w/w.

### Claim 38 (depends on 36)

A composition according to claim 36, wherein the solubilizing agent is PtrienS-600, and wherein the ratio of PtrienS-600 to coenzyme Q10 is 3.5:1 w/w. 2.5:1 w/w.

### Claim 39

A water-soluble composition comprising a bioactive lipophilic compound and a solubilizing agent of the general formula
{X—OOC—[(CH2)n—COO]m}p—Y
wherein:
p is 1 or 2,
m is 0 or 1, and
n is an integer in the range O≦n≦18
X is a residue of a hydrophobic moiety selected from the group consisting of cholesterol, 7-dehydrocholesterol, campesterol, sitosterol, ergosterol, stigmasterol, and α-, β-, γ-, and Δ-tocopherols and derivatives thereof, Y is a residue of a hydrophilic moiety, selected from the group consisting of polyalcohols, polyethers, polyanions, polycations, polyphosphoric acids, polyamines, polysaccharides, polyhydroxy compounds, polylysines and derivatives thereof, provided that:
when p and m are equal to 1 and the hydrophobic moiety is (+)-α-tocopherol, n is not equal to 2.

### Claim 40 (depends on 39)

A composition according to claim 39, wherein the bioactive lipophilic compound is selected from the group consisting of ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, and mixtures thereof provided that:
when the bioactive lipophilic compound is ubiquinone and the hydrophobic moiety is cholesterol, n is not equal to 8.

### Claim 41 (depends on 39)

A composition according to claim 39, where the hydrophilic moiety is PEG-400.

### Claim 42

A method for making polyoxyethanyl tocotrienyl sebacate, comprising:
a) dissolving a tocotrienol in an organic solvent,
b) reacting the solution with a compound of the general formula Z—OC—(CH2)n—CO—Z, where Z is a leaving group, and
c) reacting with a compound of the general formula HO—Y—OR, wherein R is hydrogen or an alkyl, and n is from 0 to 18.
